Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Dorsey & Whitney Trust CO LLC

Dorsey & Whitney Trust CO LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.7% in the fourth quarter, HoldingsChannel reports. The firm owned 636 shares of the biopharmaceutical company’s stock after selling 84 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Regeneron Pharmaceuticals were worth $453,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Proficio Capital Partners LLC lifted its stake in Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after buying an additional 219,162 shares during the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $127,489,000. KBC Group NV lifted its position in Regeneron Pharmaceuticals by 296.7% in the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after purchasing an additional 102,198 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $65,180,000. Finally, Icon Wealth Advisors LLC grew its position in Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after purchasing an additional 75,569 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $744.83 on Tuesday. The stock has a market capitalization of $81.43 billion, a P/E ratio of 19.46, a P/E/G ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The business’s fifty day moving average is $696.96 and its two-hundred day moving average is $845.58. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $11.86 earnings per share. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.47%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on REGN. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Bank of America reaffirmed an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. Finally, TD Cowen reduced their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.